Free CME

Sharper Focus on Geographic Atrophy: Imaging-Based Strategies for Retina Specialists is an educational initiative designed to equip retina specialists, comprehensive ophthalmologists, and other members of the multidisciplinary ophthalmology care team with practical, evidence-based strategies for the diagnosis, monitoring, and management of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Despite advances in retinal imaging and the emergence of complement inhibitor therapies, GA remains underrecognized and inconsistently managed in clinical practice. Variability in the interpretation of multimodal imaging, the lack of standardized monitoring, and gaps in understanding the complement system’s role in disease progression continue to challenge coordinated, patient-centered care. Delayed referral, limited patient understanding of the disease course, and barriers to adherence with monitoring schedules can further delay timely intervention and complicate long-term management.

This activity is derived from a Live ISS at ASRS, originally held on July 17, 2026.

This activity addresses these gaps by reviewing the clinical and multimodal imaging features that distinguish early and intermediate AMD from GA, the lesion-progression patterns that signal worsening disease, and the role of complement dysregulation in GA pathogenesis. Faculty will also examine the mechanisms of action, candidate selection, and integration of complement inhibitor therapies into evidence-based care pathways for patients with GA secondary to AMD.

Through expert-led, case-based discussion, participants will strengthen their ability to interpret imaging findings with greater confidence, implement structured monitoring strategies, and deliver more coordinated, individualized care. Faculty will anchor the discussion in multimodal imaging and use animations of disease pathophysiology and treatment mechanisms, interactive Q&A, and collaborative problem-solving, closing with key takeaways and practical tips for GA monitoring. The program is delivered as a live, interactive industry-supported symposium (ISS) and is intended for retina specialists and other members of the multidisciplinary ophthalmology care team involved in the management of GA secondary to AMD in the United States.

This accredited activity reviews advancements in lung transplant surgery, with a focus on robotic lung transplant and ex vivo lung perfusion.

Meet a 52-year-old woman with type 2 diabetes and hypertension whose recent laboratory results reveal a decline in kidney function. How would you manage this patient? In this 15-minute activity, read about next steps in the management of advanced kidney disease.

MPN care is advancing fast, but translating molecular findings, prognostic scores, and symptom data into a coherent, risk-adapted plan remains a real challenge at the point of care. This symposium gives the full care team a practical framework — so you can stratify risk accurately, select therapy with confidence, and personalize treatment across PV, ET, and MF. As novel mechanisms of action, combination regimens, and anemia-targeting therapies enter the MPN landscape, clinicians face growing uncertainty about where each option fits. Learn to evaluate emerging and established therapies side by side, anticipate and manage adverse events, and deliver comprehensive, longitudinal care that improves outcomes.

The integration into practice of sustained delivery devices and therapies that offer longer duration of action have further revolutionized the management of patients with diabetic macular edema (DME). However, selecting patients who will optimally benefit from these newer therapies can be challenging. Biomarkers of vascular instability are emerging, which could help guide treatment decisions and provide useful tools for monitoring disease control. This CE activity utilizes Curbside Consults, a dynamic and interactive case-based platform that will highlight these therapeutic strategies for the management of DME that reduce dosing frequency and enhance anatomic outcomes. Experts in the field also review the role of novel biomarkers to guide early clinical decision-making and evaluate treatment options for patients with DME based on the latest clinical evidence.

In this online, self-learning activity:

Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular junction disorder marked by fluctuating, fatigable weakness that can involve ocular, bulbar, limb, and respiratory muscles. In a U.S. claims-based analysis, diagnosed prevalence in 2021 was 37.0 per 100,000 and incidence was 3.1 per 100,000, underscoring a clinically meaningful population at risk for disability and episodic deterioration. Reviews describe persistent symptom burden and functional consequences that extend beyond clinic-based strength testing. Real-world observational data link higher disease severity to greater impairment in activities of daily living, including reduced independence with self-care and mobility. International consensus guidance recommends stepwise management with early steroid-sparing intent and timely adjustment when treatment targets are not met. Higher severity is also associated with worse work productivity and activity impairment, amplifying socioeconomic burden.

UTI at the Point of Care: Diagnostic and Treatment Decisions That Matter is a blended-learning curriculum designed for primary care clinicians, urologists, gynecologists, and other members of the health care team who treat patients with uncomplicated urinary tract infections (uUTIs). Although uUTIs are among the most common infections prompting antibiotic use, nearly half of prescriptions remain inappropriate or non–guideline-concordant. Through interactive, case-based discussion with expert faculty and peers, participants will practice distinguishing uUTI from asymptomatic bacteriuria, complicated UTI, and pyelonephritis. Participants will review guideline-concordant regimens, including novel agents, informed by local resistance patterns and antimicrobial stewardship principles. Participants will also apply risk-based stratification to guide urine culture use and therapy selection. Finally, participants will develop patient-centered strategies that reduce the burden of uUTIs on patients and the health care system.

In this online, self-learning activity:

Osteoporosis in aging men is a growing public health problem yet remains under-recognized in primary and specialty care. Population-based cohorts show that adults aged ≥80 years now account for most hip fractures, and in this age group men experience higher perioperative morbidity and mortality than women at comparable ages. Contemporary US trend analyses confirm a high and in some groups increasing prevalence of osteoporosis and low bone mass among adults ≥50 years, with substantial burden among older men. Health-economic models and actuarial reports estimate more than two million osteoporotic fractures annually in the United States, costing about $17 billion in 2005 and rising to an estimated $57 billion over the past two decades, with further growth expected by 2040; men already account for more than one-quarter of this burden. Prospective outcomes work from the ICUROS US study and Medicare claims analyses underscores prolonged quality-of-life loss and markedly higher all-cause costs after fragility fractures, especially hip and vertebral fractures in older adults, including men.

Hear from a panel of clinicians from community practices about their experiences, including the challenges and successes, with integrating B-cell maturation antigen (BCMA)-directed bispecific antibodies into their practices. Explore patient management strategies for bispecific antibodies, from starting treatment at a community center to providing long-term care after treatment initiation at either a community or tertiary center.

Explore recent findings in Pain Reprocessing Therapy with Yoni K. Ashar, PhD. This free lecture connects emerging research with assessment, patient education, and treatment planning for chronic pain.

Discuss consequences of delayed or inter­rupted treatment for nAMD
Describe efficacy and safety of newer anti-VEGF treatments for nAMD
Jointly provided by Partners for Advancing Clinical Education and DKBmed, LLC

This MedHive™ workshop convenes expert faculty in a case-based, peer-driven format to help interprofessional teams individualize hepatocellular carcinoma (HCC) treatment while preserving hepatic reserve and quality of life. Faculty will translate clinical trial and real-world evidence into practical selection among immune checkpoint inhibitor (ICI)–based regimens for advanced disease, including in patients with impaired liver function or other high-risk features. Throughout, faculty will model multidisciplinary coordination, shared decision-making, and structured monitoring of liver function and treatment-related toxicity across the care continuum.

In this online, self-learning activity:

Neonatal respiratory distress syndrome (nRDS) remains a leading cause of respiratory failure and morbidity among preterm infants worldwide, despite major advances in antenatal steroids, continuous positive airway pressure (CPAP), and surfactant therapy. Contemporary guidelines emphasize early noninvasive respiratory support from birth, selective surfactant rescue once CPAP begins to fail, and structured, protocolized care across gestational age strata. Yet practice-pattern studies across high- and middle-income settings show wide variation in initial respiratory support, surfactant thresholds, and use of minimally invasive techniques, with extremely preterm and late preterm infants often receiving care that diverges from guideline-concordant pathways. These inconsistencies increase cumulative ventilator exposure and risk of bronchopulmonary dysplasia (BPD) and other complications, underscoring a persistent implementation gap between best evidence and routine NICU care.

Listening First: Shared Decisions That Build Trust in Pediatric Obesity Care is a CME activity designed to support pediatricians in delivering effective, evidence-based care to children and adolescents with obesity. Despite the growing prevalence and risks of pediatric obesity, many clinicians face barriers such as limited training, low confidence, and discomfort initiating sensitive conversations.

This activity provides practical guidance on guideline-recommended screening, culturally and developmentally appropriate communication strategies, and the development of individualized treatment plans. With a focus on shared decision-making and building trust with families, participants will gain the tools needed to improve patient engagement and outcomes in pediatric obesity care.

Pri-Med’s CME courses are designed with primary care physicians in mind. We cover topics that reflect a typical day in primary care practice, and our CME courses offer AMA PRA Category 1 Credits™ and ABIM Medical Knowledge MOC Points to help you fulfill your state and board requirements. Choose from hundreds of online physician CME courses across 50 therapeutic areas and learn key insights from expert clinician-educators.

Upon completion of this activity, learners will be able to:

• Implement routine OSA screening for patients with obesity and other OSA risk factors.
• Identify tools that can aid in screening patients for OSA.
• Initiate diagnostic workups for patients with suspected OSA.
• Evaluate results from OSA diagnostic studies.
• Implement multidisciplinary approaches to formulate tailored management strategies for OSA that account for patient preferences and new therapeutic options.

Pri-Med’s CME/CE courses are designed with primary care doctors in mind. We cover topics that reflect a typical day in primary care practice, and our CME/CE courses offer AMA PRA Category 1 Credits™ to help you fulfill your state and board requirements. Choose from hundreds of online CME/CE courses across 40 therapeutic areas and learn key insights from expert clinician-educators that you can apply immediately to your practice.

Bronchiectasis is a complex and increasingly prevalent condition often overlooked in clinical practice, with frequent overlap with other respiratory diseases such as COPD and asthma. Persistent airway inflammation, chronic infection, and mucociliary dysfunction drive disease progression, leading to significant morbidity and healthcare burden. As the clinical burden of bronchiectasis becomes increasingly recognized, there is an urgent need to better understand the underlying mechanisms of neutrophilic inflammation, alongside efforts to improve early diagnosis and explore current and emerging treatment options that target this vicious cycle.

In this activity, a panel of leading pulmonologists tackle the evolving challenges and emerging opportunities in bronchiectasis management. From diagnostic workup to airway clearance and exacerbation control, the discussion will blend expert insight with real-world clinical scenarios and patient perspectives.
Endocrinologists, endocrinology NPs and PAs, and the broader care team are positioned to close it. This training program, modeled on the CDC Training of Trainers approach, equips endocrinology-led teams to build CKM risk into everyday T2D decision-making: selecting and sequencing GLP-1-based therapies according to a patient’s cardiovascular, renal, and metabolic profile, not glycemic control alone. The content also addresses related benefits emerging in this drug class, including MASH and OSA, within the broader CKM framework.Designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025
Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.

This MedHive™ educational initiative focuses on empowering endocrinologists to deliver personalized, evidence-based care for patients with type 2 diabetes. Through interactive peer discussions and expert insights, participants will contribute their collective knowledge to explore strategies to optimize therapy selection, improve adherence, and achieve both glycemic and extra-glycemic goals aligned with the latest 2025 ADA Standards of Care.